co.don AG Shareholders' meeting adopts capital increase

• ¤3.9 million fresh capital for the biopharma company

Teltow/Berlin On 8 August 2012 the shareholders' meeting of biopharmaceutical company co.don AG (ISIN DE000A1K0227) approved a proposal for a capital increase put forward by the Executive Board and Supervisory Board. The shareholders voted to create new approved capital of ¤3,554,292. This increases the company's share capital from ¤7,108,584 to ¤10,662,876. Two investors have already committed to purchase the 3,554,292 new shares at a price of ¤1.10 per share. As a result of acquiring the two new investors - TRANS NOVA INVESTMENTS LIMITED and OSEMIFARO INVESTMENTS LTD - co.don AG will receive proceeds of around ¤3.9 million.

"This new investment secures the funding of our company", said Dr. Andreas Baltrusch, CEO of co.don AG. "In particular the fresh capital will cover the substantial expenses for the two clinical trials needed to apply for approval by the European Medicines Agency (EMA)."
Approval is a fundamental requirement for a European central marketing authorisation and is mandatory from 2013. The company is working all out on several pre-clinical and clinical trials for its main product, co.don chondrosphere®. In 1997 co.don AG became the first company in Europe to receive production authorisation for autologous chondrocyte transplants. More than 4,500 patients have been treated with its patented methods to date. Last year co.don AG was voted Entrepreneur of the Year by the Association of East German Savings Banks.

The shareholders' meeting also passed a resolution to expand the Supervisory Board from three to six members. The newly elected Supervisory Board members are Mr Thomas Krause, Potsdam, Mr Stig Jarle Petterson, Oslo and Dr. Andrei Petrov, Moscow.

co.don AG is a leading innovator in the production of autologous chondrocyte transplants and has continued its positive business development in 2012. In the first half of 2012 revenue rose to ¤1,251 million, an increase of some 7 per cent on the same period last year. Sales in the domestic German market in particular were up by more than 10 per cent in the first six months.

The attendance figures and the result of voting on the agenda items for the shareholders' meeting can be found at: http://www.codon.de/investors/shareholders-meeting.html?L=1

About co.don^® AG:

The company is based in Teltow, Brandenburg, and was founded in 1993. Since 2001 the biopharmaceutical specialist has been listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). co.don AG^® uses tissue engineering - the cultivation and growth of autologous tissue cells - to develop innovative products and therapeutic concepts for the orthopaedic and neurosurgical markets. The cell-based biological drugs (autologous cell transplants for articular cartilage and intervertebral disks) are produced without the use of antibiotics, growth factors and genetic engineering. The Executive Board of co.don^® AG is made up of Dr Andreas Baltrusch (CEO) and Vilma Siodla (COO).

Further information is also available at: www.codon.de